Isofol Announces Topline Results of Phase III AGENT Study – Did Not Meet Primary or Key Secondary Endpoints
GOTHENBURG, Sweden, August 3, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced topline results that neither the…
Privacy & Cookies Policy
These cookies are necessary for the website to function properly. These cookies ensure basic functionalities and security features of the website. These cookies do not store any personally identifiable information.